Trovagene has commercially launched its urine-based HPV-HR (high-risk) assay, a molecular human papillomavirus (HPV) test.
Using proprietary DNA sequences, the non-invasive molecular diagnostic test will identify the presence or absence of fifteen known high-risk HPV strains.
The urine-based HPV-HR DNA test can facilitate more comprehensive patient monitoring for women who wish to avoid repeated physical exams, but still need monitoring for their HPV status.
Trovagene CEO Antonius Schuh said that the launch of urine-based HPV-HR DNA test represents an important milestone for the company.
"Non-invasive carrier testing may help to increase awareness of HPV status and could reduce the incidence of HPV-related cervical cancer and other cancers worldwide," Schuh added.
The Centers for Disease Control and Prevention estimates that around 20 million Americans carry HPV, with six million new cases occurring every year.
